Biocryst looks to raise the profile of its factor D inhibitor

Biocryst stock is up 120% since the start of December, and the group’s oral factor D inhibitor BCX9930 might be one reason why. The sellside has previously not paid this pipeline asset much attention, but with clinical data due within weeks this might change.